NAOV vs. NUWE, TIVC, CTCX, CHEK, TNON, SINT, HSCS, AMIX, NDRA, and GMVDF
Should you be buying NanoVibronix stock or one of its competitors? The main competitors of NanoVibronix include Nuwellis (NUWE), Tivic Health Systems (TIVC), Carmell (CTCX), Check-Cap (CHEK), Tenon Medical (TNON), Sintx Technologies (SINT), Heart Test Laboratories (HSCS), Autonomix Medical (AMIX), ENDRA Life Sciences (NDRA), and G Medical Innovations (GMVDF). These companies are all part of the "medical equipment" industry.
NanoVibronix vs.
Nuwellis (NASDAQ:NUWE) and NanoVibronix (NASDAQ:NAOV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings.
NanoVibronix received 49 more outperform votes than Nuwellis when rated by MarketBeat users. Likewise, 57.26% of users gave NanoVibronix an outperform vote while only 53.66% of users gave Nuwellis an outperform vote.
NanoVibronix has lower revenue, but higher earnings than Nuwellis. NanoVibronix is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
NanoVibronix has a net margin of -93.80% compared to Nuwellis' net margin of -169.54%. NanoVibronix's return on equity of -101.17% beat Nuwellis' return on equity.
3.1% of Nuwellis shares are held by institutional investors. Comparatively, 16.4% of NanoVibronix shares are held by institutional investors. 2.6% of Nuwellis shares are held by company insiders. Comparatively, 7.0% of NanoVibronix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nuwellis has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Nuwellis currently has a consensus price target of $17.00, suggesting a potential upside of 1,207.69%. Given Nuwellis' stronger consensus rating and higher probable upside, equities research analysts plainly believe Nuwellis is more favorable than NanoVibronix.
In the previous week, Nuwellis had 3 more articles in the media than NanoVibronix. MarketBeat recorded 3 mentions for Nuwellis and 0 mentions for NanoVibronix. NanoVibronix's average media sentiment score of 0.00 beat Nuwellis' score of -0.34 indicating that NanoVibronix is being referred to more favorably in the news media.
Summary
NanoVibronix beats Nuwellis on 12 of the 19 factors compared between the two stocks.
Get NanoVibronix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAOV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoVibronix Competitors List
Related Companies and Tools
This page (NASDAQ:NAOV) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NAOV Stock Alerts